More problems for BioNTech & Roche’s neoantigen shot
Autogene cevumeran goes on hold in adjuvant bladder cancer.
Autogene cevumeran goes on hold in adjuvant bladder cancer.
Controversial nods came for Urogen’s Zusduri and Astra/Daiichi’s Datroway.
Astra/Daiichi have trumped Gilead’s Trodelvy with a lung cancer approval.
Zanzalintinib prevails in all comers, but full data will show if the win was driven by a subgroup.
But the former is paying a fraction of what Merck shelled out for raludotatug.
The move follows promising but early data presented at ASCO.
BNT327 could rival Keytruda and Opdivo, but toxicity is worth watching.
Gilead’s TROP2 ADC sets the bar for Astra/Daiichi’s Datroway in first-line TNBC.